Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EBIT: 2011-2025

Historic EBIT for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to $51.0 million.

  • Adma Biologics' EBIT rose 28.69% to $51.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $167.0 million, marking a year-over-year increase of 45.36%. This contributed to the annual value of $139.0 million for FY2024, which is 542.49% up from last year.
  • Per Adma Biologics' latest filing, its EBIT stood at $51.0 million for Q3 2025, which was up 19.19% from $42.8 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' EBIT peaked at $51.0 million during Q3 2025, and registered a low of -$15.6 million during Q2 2021.
  • Its 3-year average for EBIT is $26.3 million, with a median of $34.9 million in 2025.
  • In the last 5 years, Adma Biologics' EBIT fell by 4.61% in 2021 and then soared by 8,387.74% in 2024.
  • Quarterly analysis of 5 years shows Adma Biologics' EBIT stood at -$13.2 million in 2021, then surged by 54.07% to -$6.1 million in 2022, then skyrocketed by 334.93% to $14.2 million in 2023, then spiked by 169.25% to $38.3 million in 2024, then rose by 28.69% to $51.0 million in 2025.
  • Its last three reported values are $51.0 million in Q3 2025, $42.8 million for Q2 2025, and $34.9 million during Q1 2025.